Seidel-Dugan Cynthia 4
4 · Werewolf Therapeutics, Inc. · Filed Jan 14, 2022
Insider Transaction Report
Form 4
Seidel-Dugan Cynthia
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2022-01-12$1.56/sh+24,199$37,750→ 149,356 total - Award
Stock Option (right to buy)
2022-01-06+79,516→ 79,516 totalExercise: $11.55Exp: 2032-01-05→ Common Stock (79,516 underlying) - Exercise/Conversion
Common Stock
2022-01-12$4.77/sh+15,532$74,088→ 164,888 total - Exercise/Conversion
Stock Option (right to buy)
2022-01-12−24,199→ 36,937 totalExercise: $1.56Exp: 2030-05-19→ Common Stock (24,199 underlying) - Exercise/Conversion
Stock Option (right to buy)
2022-01-12−15,532→ 83,631 totalExercise: $4.77Exp: 2030-12-07→ Common Stock (15,532 underlying)
Footnotes (3)
- [F1]The option was granted on January 6, 2022 with a Vesting Commencement Date of January 1, 2022. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through January 1, 2026.
- [F2]The option was granted on May 20, 2020 with a Vesting Commencement Date of June 1, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through June 1, 2024.
- [F3]The option was granted on December 8, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024.